Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04708886 · ClinicalTrials.gov registry record · Phase 2
Romosozumab in Women With Chronic SCI
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT04708886 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 12 participants.
The verdict
NCT04708886, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This two-year open-label pilot clinical trial will evaluate the efficacy and safety of romosozumab to treat bone loss in females with chronic spinal cord injury (SCI) and osteoporosis (OP). Participants will receive monthly injections of romosozumab during the first 12 months of the study. During the second year, participants will take oral alendronate tablets on a weekly basis.
Interventions
- DRUG Romosozumab
- DRUG Alendronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2024-06-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04708886
The ClinicalTrials.gov registry entry for NCT04708886 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Romosozumab is the first listed.
NCT04708886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04708886 about?
NCT04708886 is a clinical study titled "Romosozumab in Women With Chronic SCI". This two-year open-label pilot clinical trial will evaluate the efficacy and safety of romosozumab to treat bone loss in females with chronic spinal cord injury (SCI) and osteoporosis (OP). Participants will receive monthly injections of romosozumab during the first 12 months of the study. During th...
What is the current status of trial NCT04708886?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-03-01. Estimated completion is 2024-06-10.
What interventions are being tested in trial NCT04708886?
The interventions under investigation include: Romosozumab (DRUG), Alendronate (DRUG).
Who is sponsoring clinical trial NCT04708886?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.